Using a tissue microarray prepared using a subset of samples from patients enrolled in ICON7 trial, it has been shown that high c‐MET/VEGFR‐2 co‐localisation on tumour tissue was shown to be associated with poorer survival outcomes in bevacizumab‐treated patients; moreover, from the same trial, patients bearing the specific VEGFR‐2 rs2305945 G/G variant had shorter PFS when treated with bevacizumab.80 Here, KDR is linked to neoplasm.